Literature DB >> 15936818

Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.

Timo Siitonen1, Pirjo Koistinen, Eeva-Riitta Savolainen.   

Abstract

The effects of valproate and butyrate were investigated in an acute myeloblastic cell line (OCI/AML-2) on cytotoxicity, cell cycle profile and expression of cell cycle regulating proteins in the presence of cytarabine (Ara-C) and etoposide. As a single agent valproate and butyrate inhibited AML cell growth but did not significantly induce cell death. A dramatic increase in cytotoxicity was observed when combining valproate or butyrate with Ara-C, whereas, co-addition of them with etoposide had much smaller effect on cell death. Valproate induced a clear G1 phase arrest and up-regulated cyclin D1 expression in the presence of Ara-C and etoposide. In addition, valporate was able to block the Ara-C-induced down-regulation of p27(Kip1) expression but not that induced by etoposide.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936818     DOI: 10.1016/j.leukres.2005.04.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.

Authors:  Chengzhi Xie; Holly Edwards; Xuelian Xu; Hui Zhou; Steven A Buck; Mark L Stout; Qun Yu; Jeffrey E Rubnitz; Larry H Matherly; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2010-10-01       Impact factor: 12.531

Review 2.  The role of HDACs inhibitors in childhood and adolescence acute leukemias.

Authors:  Riccardo Masetti; Salvatore Serravalle; Carlotta Biagi; Andrea Pession
Journal:  J Biomed Biotechnol       Date:  2011-01-13

3.  Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

Authors:  S R Green; A K Choudhary; I N Fleming
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

4.  Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature.

Authors:  Antonella Poloni; Benedetta Costantini; Marianna Mariani; Pietro Leoni
Journal:  Leuk Res Rep       Date:  2013-06-11

5.  Interpreting clinical assays for histone deacetylase inhibitors.

Authors:  Nadine Martinet; Philippe Bertrand
Journal:  Cancer Manag Res       Date:  2011-05-09       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.